TIMP3 mRNA levels were found to be ∼10–13-fold higher in the cancer cells treated with EZH2-specific shRNA (sh1) than control cells untreated with the shRNA (Figure 3A), and as a result, TIMP3 protein levels were significantly increased by knockdown of EZH2 expression (Figure 3B). This evidence concerns the gene TIMP3 and cancer.